Menu
Search
|

Menu

Close
X

Apellis Pharmaceuticals Inc APLS.OQ (NASDAQ Stock Exchange Global Select Market)

14.46 USD
+0.79 (+5.78%)
As of Nov 15
chart
Previous Close 13.67
Open 13.64
Volume 81,715
3m Avg Volume 101,880
Today’s High 14.73
Today’s Low 13.64
52 Week High 31.69
52 Week Low 11.45
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.681
FY17
-1.036
FY16
-0.281
FY15
-0.800
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
--
5.95
Price to Book (MRQ)
vs sector
--
4.89
Price to Cash Flow (TTM)
vs sector
--
22.90
Total Debt to Equity (MRQ)
vs sector
--
17.74
LT Debt to Equity (MRQ)
vs sector
--
13.15
Return on Investment (TTM)
vs sector
--
14.22
Return on Equity (TTM)
vs sector
--
15.99

EXECUTIVE LEADERSHIP

Gerald Chan
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Cedric Francois
President, Chief Executive Officer, Co-Founder, Director, Since 2016
Salary: $400,000.00
Bonus: $225,000.00
Pascal Deschatelets
Co-Founder, Chief Operating Officer, Since 2016
Salary: $279,227.00
Bonus: $120,000.00
Timothy Sullivan
Chief Financial Officer, Treasurer, Since 2017
Salary: $68,939.00
Bonus: $40,000.00
Federico Grossi
Executive Vice President - Clinical Development, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

6400 Westwind Way Ste a
CRESTWOOD   KY   40014-6773

Phone: +1502.2414114
Site: apellis.com/

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.

SPONSORED STORIES